Form 4: VolitionRx CEO, Jasmine Kway, Receives Stock Award in Lieu of Cash Compensation

Jasmine Kway, CEO of VolitionRx Singapore, received 15,169 restricted stock units in lieu of cash compensation.

Summary

• Jasmine Kway, CEO of VolitionRx Singapore, was awarded 15,169 restricted stock units (RSUs) on December 1, 2024.
• These RSUs were granted under the company's 2015 Stock Incentive Plan as a substitute for cash compensation.
• The RSUs vest in three installments of 5,057, 5,056, and 5,056 units on December 1, 2024, January 1, 2025, and February 1, 2025, respectively.
• A final vesting installment occurs on July 1, 2025, subject to continued service.
• Upon vesting, Kway will receive common stock equal to the number of vested RSUs.
• Kway also has 10,400 shares of common stock held indirectly by her spouse.

Sentiment

Score: 7

Explanation: The document is neutral to slightly positive as it details a standard executive compensation practice. The use of RSUs instead of cash is a positive sign for cash preservation.

Positives

• The use of RSUs instead of cash compensation may help preserve the company's cash reserves.
• The vesting schedule incentivizes continued service from the CEO.

Risks

• The value of the RSUs is tied to the company's stock price, which can fluctuate.
• The vesting of the RSUs is contingent on continued service, which could be a risk if the CEO were to leave the company.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

The use of stock-based compensation is a common practice in the biotechnology industry to attract and retain key executives, especially in companies that may be prioritizing cash preservation.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the biotech industry, with companies like Exact Sciences (EXAS) and Guardant Health (GH) also using stock options and RSUs as part of their executive compensation packages.
• The vesting schedule of the RSUs is typical, with vesting occurring over multiple years to incentivize long-term commitment.
• The amount of RSUs awarded is not directly comparable without knowing the specific compensation structure of other companies, but it is within the range of what is seen in similar-sized biotech firms.

Stakeholder Impact

• Shareholders may view the use of RSUs positively as it conserves cash.
• Employees may see this as a standard practice for executive compensation.

Key Dates

Keywords

restricted stock units, RSUs, stock compensation, insider trading, executive compensation, VolitionRx, VNRX, Jasmine Kway